Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

May 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-04-30

Reporting Person: Perry Nicole D (Vice President - Accounting)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-30	Common Stock	M	1000	$3.76	Acquired	5847	Direct
2021-04-30	Common Stock	S	1000	$50.00	Disposed	4847	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-30	Stock Option (Right to Buy)	$3.76	M	1000	Disposed	2025-07-31	Common Stock (1000)	Direct

Footnotes

F1: This is a scheduled exercise from a 10B5-1 trading plan.

F2: This option was granted on July 31, 2015 and is fully vested.